“Collaborating with a group of highly passionate, skilled individuals to create transformative change for underserved patients is the reason why I do what I do.”
Jung joined TRV as a part-time EIR in 2023. She is passionate about transformative changes in people’s lives by delivering the best therapies science can create. What gets her up in the morning is the possibility of life-changing benefits, especially for underserved people living with difficult diseases.
Jung has led at the intersection of science and business. Prior to TRV, she was Chief Business & Strategy Officer at Global Blood Therapeutics, where she led Corporate Development, R&D Program Management & Portfolio Strategy, Patient Advocacy and Government Affairs/Policy, and was instrumental in building a pipeline of novel therapies for sickle cell disease. She cut her teeth as head of Corporate Development at Gilead Sciences, InterMune, and Chimerix, and started her career at McKinsey and Bay City Capital. She is an expert in strategic deal making, having led or managed >50 transactions exceeding $17 billion in value. She serves on the Board of Annexon (NASDAQ: ANNX), New York Blood Center Enterprises, and California Life Sciences. She is also an Aspen Institute Health Innovator Fellow.
Outside the office, Jung can be found watching her two sons’ baseball games, hiking, skiing, traveling with her family, and working on her yoga asanas.